Please Choose Your Language
Views: 0 Author: Site Editor Publish Time: 2026-09-07 Origin: Site
For India's API and intermediate ecosystem, 5-nitro-2-aminophenol is best understood as a niche building block: useful in selected synthesis routes, important to verify carefully, but not a universal shortcut to finished APIs. This guide explains how CAS 121-88-0 fits pharmaceutical R&D, what purity questions matter, and how Indian buyers can evaluate supply options.
5-NAP combines amino, hydroxyl, and nitro groups on one aromatic ring. That structure makes it a flexible starting material for reactions that need diazotization, coupling, reduction, or heterocycle formation.
CAS: 121-88-0.
Formula: C6H6N2O3.
Molecular weight: 154.12.
Positioning: specialty intermediate for R&D and selected synthetic routes, not a finished API.
Published product and literature references connect 5-NAP with the synthesis of benzoxazinone derivatives and other biologically active molecules. In practical terms, its value is the functional-group pattern that can be carried into more complex scaffolds.
Chemistry role | Buyer implication |
|---|---|
Heterocycle construction | Useful for R&D teams screening scaffold routes |
Diazotization/coupling | Supports aromatic derivatization work |
Nitro group transformation | Can support downstream reduction or functionalization plans |
Routes through protected aminophenol intermediates are used to manage positional selectivity. Direct nitration routes can be useful in lab references, but industrial buyers should focus on reproducible impurity control rather than route description alone.
Confirm the intended synthesis route and target grade.
Request HPLC assay and known impurity data.
Check melting point as a practical identity screen.
Validate the sample in the downstream reaction before approving bulk supply.
India's API sector is actively working to reduce dependence on imported key starting materials and drug intermediates. That makes imported specialty intermediates like 5-NAP relevant to procurement teams, especially when domestic alternatives are not immediately qualified.
API and intermediate buyers need repeatable quality, not only spot availability.
PLI and bulk-drug localization programs increase attention on KSM and intermediate traceability.
Chinese export supply can still be useful when documentation, sample approval, and logistics are handled clearly.
Requirement | What to ask for |
|---|---|
Identity | CAS 121-88-0, synonym list, and analytical identity |
Purity | HPLC assay and impurity profile |
Safety | Current SDS and transport classification |
Traceability | Batch number, manufacturing date, and COA |
Change control | Notification if route, site, or specification changes |
If the material will enter a regulated development chain, define whether it is a research reagent, intermediate, KSM candidate, or non-GMP upstream raw material.
5-NAP should be handled as a chemical intermediate with documented hazards. Buyers should not assume that a high assay automatically makes it suitable for regulated pharmaceutical use. The regulatory boundary depends on the route, the stage at which the material enters the process, and the buyer's quality system.
Review SDS hazards before import and storage.
Define whether GMP expectations apply to the stage where the material is used.
Keep COA, SDS, invoice, and import records aligned by batch.
Do not use supplier marketing claims as regulatory evidence.
Indian teams may buy lab packs from catalog suppliers during route scouting, then move to bulk suppliers after the route is fixed. The transition should include sample qualification, method comparison, impurity review, and logistics checks.
Request pharma-intermediate 5-NAP details from AquaChem
No. It should be treated as an intermediate or research building block, depending on the route.
Many buyers request 98-99% HPLC, but the correct limit depends on the downstream route and impurity risk.
Because Indian buyers increasingly evaluate intermediate supply through the lens of localization, documentation, and supply-chain resilience.
5-Nitro-2-aminophenol can be useful in pharmaceutical synthesis when the route genuinely needs its aminonitrophenol structure. For India-focused procurement, the responsible approach is to validate chemistry fit, impurity profile, regulatory boundary, and supplier documentation before scaling.
Ask AquaChem for 5-NAP COA and supply details
Pharmaceutical R&D teams should qualify 5-NAP according to the stage of development. In early screening, a catalog-grade or sample lot may be enough to test chemistry feasibility. As the route matures, the team should tighten identity, assay, impurity, and change-control requirements. The same molecule can move from research material to controlled intermediate only when documentation keeps up with the process risk.
The key question is not whether 5-NAP is 'pharma grade' in a generic sense. The better question is whether the batch specification supports the buyer's route, impurity fate, and quality system. A supplier who understands that distinction is more valuable than one who simply lists a high assay.
In pharmaceutical synthesis, an impurity can disappear, carry through, react into a related substance, or interfere with purification. Buyers should ask which impurities are known, how they are measured, and whether the supplier can maintain a stable impurity profile across repeat batches. For early development, this prevents surprises when the route is scaled.
Check whether positional isomer impurities are controlled.
Ask whether heavy metals or residue on ignition are relevant to the route.
Compare supplier COA data with the buyer's own incoming test method.
Keep retain samples from approved lots for troubleshooting.
India's API industry is paying closer attention to key starting materials, drug intermediates, and import dependence. Specialty intermediates such as 5-NAP may not be the center of national API policy, but they sit inside the broader procurement reality: buyers want dependable supply, transparent documents, and the ability to qualify alternatives before a shortage occurs.
For an India-focused article, the honest message is therefore balanced. 5-NAP can support selected bioactive molecule synthesis and R&D routes, while AquaChem can be presented as an export supplier for evaluation. It should not be overstated as a major API driver without route-specific evidence.
When a new supplier batch enters a pharmaceutical development program, the sourcing team should brief QA on how the material will be used. Is it only for exploratory chemistry, or will data from this batch support a development decision? Will impurities be purged later, or could they carry into an isolated intermediate? These questions decide how strict incoming testing should be.
For early R&D, flexibility is normal. For later route work, uncontrolled supplier changes become expensive. A buyer may therefore keep two specifications: one for exploratory samples and one for qualified supply. That keeps procurement practical while still protecting the quality system as the project matures.
